Daiichi, an international pharmaceutical firm with operations in 10 companies, is updating its clinical development process by utilizing SAS Drug Development software.
Daiichi, which is based in Japan, said it would use the SAS suite to outsource clinical trials infrastructure so the company can “focus on core research functions”.
“Our core competency is the development of new medications, not the creation and maintenance of a clinical data management system,” said Ron Fitzmartin, vice president of Global Technical Services for Daiichi Medical Research. “This system with SAS Drug Development at its core will enable Daiichi to eliminate paper-based systems – and the inevitable errors that result from the use of these systems – and help us make quicker decisions about which compounds hold the most promise.”
SAS said its software will enable Daiichi to capture and manage data by providing electronic data capture, data integration, visualization, analysis and reporting.